Pfizer and BioNTech announced that they had submitted data to the Food and Drug Administration showing that their COVID-19 vaccine was safe and effective for children between the ages of 5 and 11.
The vaccine demonstrated a “favorable safety profile and elicited robust neutralizing antibody response” in children who had received two doses, according to the companies. The clinical trial included 2,268 participants.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.